Abstracts tagged "rituximab and treatment"

Abstract Number: 2462 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis
Francisco Javier Narváez¹, Alejandro Robles Perez², Patricio Luburich³, J Alegre⁴, Milagros Ricse⁵, Carmen Gomez Vaquero⁶, Joan Miquel Nolla⁵ and Maria Molina⁵, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of rituximab (RTX) in the medium- to long-term for the management of progressive rheumatoid arthritis–related interstitial lung disease…
Abstract Number: 27 • 2017 ACR/ARHP Annual Meeting
Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab
Roberta Fenoglio¹, Laura Solfietti¹, Savino Sciascia² and Dario Roccatello¹, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Monoclonal antibodies (MoAbs) are highly successful in treating various immunological disorders. The development of anti-drug antibodies (ADA) against the therapeutic MoAb is relatively common.…
Abstract Number: 104 • 2017 Pediatric Rheumatology Symposium
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
Esraa M. A. Eloseily^1,2, Courtney Crayne¹, Melissa L Mannion³, Saji P Azerf⁴, Peter Weiser¹, Timothy Beukelman¹, Matthew L. Stoll¹, Dan Feig⁵, Prescott Atkinson⁶ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of medicine, Univesity of Alabama at Birmingham,, Birmingham, AL, ⁵Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited, but more severe…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…
Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Ben Roberts¹, Alexander Langridge², John Wilkinson³, Elliot Jones⁴, Edward Lea², Ben Hargreaves⁵, David Walker⁶ and Martin Lee³, ¹Rheumatology, Newcastle University, Newcastle, United Kingdom, ²Rheumatology, Freeman Hospital, Newcastle, United Kingdom, ³Freeman Hospital, Newcastle, United Kingdom, ⁴Newcastle University, Newcastle, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶Rake Lane, Northumbria Healthcare, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…
Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
William Monaco¹, William F.C. Rigby² and Jonathan Jones³, ¹Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
Abstract Number: 2536 • 2014 ACR/ARHP Annual Meeting
The Sjögren’s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy
Divi Cornec¹, Valerie Devauchelle-Pensec², Xavier Mariette³, Sandrine Jousse-Joulin⁴, Jean-Marie Berthelot⁵, Aleth Perdriger⁶, Xavier Puéchal⁷, Véronique le Guern⁸, Jean Sibilia⁹, Jacques Gottenberg¹⁰, Laurent Chiche¹¹, Eric Hachulla¹², Pierre-Yves Hatron¹³, Vincent Goëb¹⁴, Gilles Hayem¹⁵, Jacques Morel¹⁶, Charles Zarnitsky¹⁷, Jean Jacques Dubost¹⁸, Raphaèle Seror¹⁹, Jacques-Olivier Pers²⁰, Emmanuel Nowak²¹ and Alain Saraux²², ¹Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ³rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ⁴Rheumatology, CHU Brest, Brest, France, ⁵Rheumatology, CHU Nantes (Nantes University Hospital), Nantes, France, ⁶Rhumatologie, Rennes, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France, ¹²Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ¹³CHU Lille, Lille, France, ¹⁴Rheumatology, Amiens University Hospital, Amiens, France, ¹⁵CHU Bichat, Paris, France, ¹⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹⁷Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ¹⁹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²⁰CHU Brest, Brest, France, ²¹CIC, CHU Brest, Brest, France, ²²Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France
Background/Purpose Efficacy of rituximab remains debated in primary Sjögren’s syndrome (pSS), but that could be partly due to the absence of validated endpoint. To determine…
Abstract Number: 1526 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year DataÂ
Catalin Codreanu¹, Ruxandra Ionescu², Ioan Ancuta³, Corina Mogosan⁴, Simona Rednic⁵, Paulina Ciurea⁶, Maria Suta⁷, Magda Parvu⁸, Andra Balanescu², Mihai Bojinca³, Dan Nemes⁹, Codrina Ancuta¹⁰ and Elena Rezus¹¹, ¹5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ⁴'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁵Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁸Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ⁹Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ¹⁰G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose Efficacy and safety of multiple courses of biologics used over extended periods of time in rheumatoid arthritis (RA) is still a medical debate. The…
Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Emily Sutton¹, Kath D. Watson², David A. Isenberg³, Anisur Rahman⁴, David Jayne⁵, Caroline Gordon⁶, Ben Parker⁷, David P. D'Cruz⁸, Munther A. Khamashta⁹, Pamela Lutalo¹⁰, Peter Lanyon¹¹, Benjamin Rhodes¹², Bridget Griffiths¹³, Edward M. Vital¹⁴, Chee-Seng Yee¹⁵, Christopher Edwards¹⁶, Mohammed Akil¹⁷, Nicola Erb¹⁸, Athiveer Prabu¹⁹, Asad A. Zoma²⁰, Neil McHugh²¹, Hazem Youssef²², Lee-Suan Teh²³, Michael W. Beresford²⁴ and Ian N. Bruce²⁵, ¹University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ⁵Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁸Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ¹⁰Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ¹¹Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹²Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ¹³Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ¹⁵Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹⁶Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁷Rheumatology Department, Sheffield South Yorkshire, United Kingdom, ¹⁸Rheumatology, Russells Hall Hospital, Dudley, United Kingdom, ¹⁹Department of Rheumatology, Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom, ²⁰Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²¹Rheumatology, Royal National Hospital, Bath, United Kingdom, ²²Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, ²³Department of Rhuematology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ²⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…
Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting
Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Ronald F. van Vollenhoven¹, Melinda Mild², Andrea Doria³, T. Dörner⁴, Gianfranco Ferraccioli⁵, Frederic Houssiau⁶, T.W.J. Huizinga⁷, David A. Isenberg⁸, László Kovács⁹, Guillermo Ruiz-Irastorza¹⁰, Danilo Squatrito¹¹, Alexandre Voskuyl¹², Marta Mosca¹³, G D Sebastiani¹⁴, Murat Inanç¹⁵, Gabriella Szücs¹⁶, Søren Jacobsen¹⁷, A. Castro¹⁸ and for The IRBIS-EMA group¹⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁶Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁹Department of Rheumatology, University of Szeged, Szeged, Hungary, ¹⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹¹Center for Autoimmune Diseases, Department of Internal Medicine, Careggi Hospital- Florence, Florence, Italy, ¹²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹³Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁴Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ¹⁵Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁶Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, ¹⁷Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ¹⁸Hospital Universitari de Reus, Spain, Reus, Spain, ¹⁹ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].